Performance of Study. IPA shall cause to be performed a Feasibility Study with respect to Interconnection Customer’s Interconnection Request in a manner consistent with Section 6 of the Procedures.
Performance of Study. IPA shall cause to be performed a System Impact Study with respect to Interconnection Customer’s Interconnection Request in a manner consistent with Section 7 of the Procedures.
Performance of Study. SPP agrees to provide all necessary labor, facilities, transportation and supervision necessary to perform the DPT Screening Study to evaluate a potential DPT. SPP shall use its sole discretion as to the scope, details and methods used to perform the Study. The Applicant agrees to compensate SPP in accordance with Sections 8.0 and
Performance of Study. SPP agrees to provide all necessary labor, facilities, transportation and supervision necessary to perform the LTSR Screening Study to provide the Applicant with an approximation of the transmission remediation costs of each potential LTSR and a reasonable cost differential between alternatives for the purpose of the Applicant’s ranking of its potential LTSRs. SPP shall use its sole discretion as to the scope, details and methods used to perform the Study. The Applicant agrees to compensate SPP in accordance with Sections 9.0 and
Performance of Study. The Transmission Provider agrees to provide all necessary labor, facilities, transportation and supervision necessary to perform the Facility Study for the Applicant to determine necessary additions to the Transmission Provider’s transmission system to provide the requested Transmission Service. The Transmission Provider shall use its sole discretion as to the scope, details and methods used to perform the Study. The Applicant agrees to compensate the Transmission Provider in accordance with Sections 7.0 and 8.0 of this Study Agreement. The Applicant will provide information as requested by the Transmission Provider.
Performance of Study. 1.1 PARTNER agrees to use its best efforts and professional expertise to perform the Study in accordance with the Plan, including any subsequent Plan amendments, all applicable legal and regulatory requirements and in accordance with the terms and conditions of this Agreement.
1.2 The PARTNER retains the sole and complete regulatory responsibility as investigator of the Study, according to the applicable law.
1.3 In the event that STUDY LEADER becomes no longer affiliated with PARTNER, PARTNER shall provide written notice to GBO within three (3) weeks of such event. In such case, PARTNER shall designate a new, equally qualified STUDY LEADER and inform GBO thereof in writing.
Performance of Study. 1.1 INSTITUTION and PRINCIPAL INVESTIGATOR agree to use their best efforts and professional expertise to perform the Study in accordance with the Protocol, all applicable legal and regulatory requirements, all written instructions and guidelines provided by the Company from time to time, including without limitation with respect to the storage, handling, use, administration and disposal of the Study Product, and in accordance with the terms and conditions of this Agreement. If INSTITUTION and/or PRINCIPAL INVESTIGATOR wish to modify the Protocol in any material respect, INSTITUTION and PRINCIPAL INVESTIGATOR shall notify COMPANY in advance of any such changes in writing. If these changes will affect the cost of the Study to be borne by COMPANY, INSTITUTION will submit to COMPANY a written estimate of such change in Study cost. COMPANY’s prior review and, in its sole discretion, acceptance of any such changes shall be required prior to implementation, and the status quo shall persist with respect to such matter until COMPANY’s consent is granted.
1.2 The INSTITUTION and PRINCIPAL INVESTIGATOR retain the sole and complete regulatory responsibility as the “sponsor” of the Study (in accordance with Art. 2 (e) of the 2001/20/EG guideline) and /or as defined at 21 CFR 312 and in guidance published by the Food and Drug Administration (“FDA”) and foreign equivalents, including for all purposes of this Agreement, all cognizant national, state and provincial drug and health regulatory agencies). Neither INSTITUTION nor PRINCIPAL INVESTIGATOR shall represent to any third party, including participants enrolled in the Study (“Subjects”), that COMPANY is a Study sponsor. Except for the funding and the Study Product to be provided by COMPANY under this Agreement, the PRINCIPAL INVESTIGATOR and/or INSTITUTION are responsible for providing, at their own expense, all facilities, personnel, equipment, tools and other supplies necessary to perform the Study under this Agreement and in accordance with the Protocol. Any funding provided by COMPANY may not be used to compensate anyone, including physicians, for referring potential Subjects for enrollment in the Study.
1.3 INSTITUTION and PRINCIPAL INVESTIGATOR certify that they have secured or will secure, if required, a Clinical Trial Application (CTA) as well as any other required regulatory authorizations, prior to enrolling Subjects in the Study. If a CTA or equivalent is required, the PRINCIPAL INVESTIGATOR agrees to supply...
Performance of Study. Transmission Owner agrees to provide all necessary labor, facilities, transportation, and supervision needed to perform the SIS and to evaluate the impact on the Transmission System caused by establishing the new Point of Interconnection as set forth the Request. Transmission Owner shall have sole discretion as to the scope, details and methods used to perform the SIS in accordance with Good Utility Practice. Requestor agrees to compensate Transmission Owner in accordance with Articles 8.0 and 9.0 of this Agreement for the work performed by Transmission Owner. The Requestor shall provide information as reasonably requested by Transmission Owner to perform the SIS as set forth in Section 7.
Performance of Study. I. 1OSF acknowledges that the Study may be performed on its premises, using its facilities at Hospital, and that the Study shall conform to the following Protocol:
I. 2OSF shall perform its duties, if any, for the Study as directed by the Principal Investigator in conformance with this Agreement, the rules, regulations and conditions of approval of the Institutional Review Board with jurisdiction over this Study, the Protocol through the verbal and written directions of the Principal Investigator, generally accepted standards of good clinical and medical practices and all applicable laws, rules, and regulations, including without limitation, HIPAA. Principal Investigator and OSF agree that any obligations imposed on Principal Investigator under the referenced Clinical Trial Agreement which require the involvement of OSF shall be discussed and agreed upon by Principal Investigator and OSF prior to the conduct of the Study at OSF under this Agreement.
I. 3Sponsor shall provide, without cost, sufficient amounts of the Study Drug/Device to allow Principal Investigator to carry out the Study. Study Drugs/Devices furnished for the Study will be used solely under the Protocol, and may not be used for any other purposes. All unused drug/device supplies shall be returned to Sponsor at the conclusion of the Study, unless written authorization to destroy them is given by Sponsor. OSF shall follow Sponsor’s instructions related to disposition of the clinical trial materials and OSF shall comply with all laws and regulations applicable to any destruction or disposition of the materials at OSF. OSF shall not release any Study drug/device to any third party (including without limitation any governmental agency, any other investigator or any other third party) without the prior written express approval from Sponsor, except in cases where OSF is required by law to release the Study drug/device to a regulatory agency acting within the scope of its regulatory authority, in which case, OSF will immediately notify Sponsor of such action.
Performance of Study. SPP agrees to provide all necessary labor, facilities, transportation and supervision necessary to perform the AFS for Applicant to determine necessary additions to the SPP transmission system to provide the requested transmission service. SPP shall use its sole discretion as to the scope, details and methods used to perform the AFS. The Applicant is responsible for its pro-rata share of the costs of the AFS in accordance with Attachment Z1, Section III.B of the Tariff. The Applicant agrees to compensate SPP in accordance with Sections 9.0 and 10.0 of this AFSA. Applicant shall provide information as requested by SPP.
